Medytox的所有产品均从研发起步。

研发管道

研发是药物研制和商业化的起点,也是实现持续增长的原动力所在。

作为一家名副其实的科研导向生物制药公司,Medytox每年的研发投资占总销售额比例超过15% – 尤其是在光教研发中心,该中心建有一套一站式体系,用于开展临床以外的全部药物研发流程,目前,我们正在开发足以领先全球市场的生物药剂。
01
挑选受试者
确保有竞争
力的技术
/ 确保成分
02
非临床研究
基于细胞
和动物的
药效与毒性测试
03
临床研究
用法用量选择
与疗效验证
04
审批
产品审批
Pipeline
Pipeline
Biopharmaceutical
Project
Indication
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Approval
Country
Neuronox®
Upperlimb Spasticity
Korea
Cerebral Palsy
Korea
Benign Essential
Eyelid Spasms.
Korea
Glabellar Line
Korea
Glabellar Line
China, Taiwan
Glabellar Line
Russia
Blepharospasm
China
Cervical Dystonia
Korea
Lateral Canthal Line
Korea
Benign Masseteric Hypertrophy
Korea
Overactive Bladder
Korea
Migraine
Korea
INNOTOX®
Glabellar Line
Korea
MT10109L Licensing out Allergan
Glabellar Line
US, Canada
Lateral Canthal Line
US, Canada
Coretox®
Glabellar Line
Korea
Upperlimb Spasticity
Korea
MT912
Macular Degeneration
-
MT925
Type 1 Diatetes
-
MT927
Immune Disorder
-
MT971
Inflammatory Bowel Disease
-
MT981
Cancers
-
바이오 의약품 그래프
Chemical Drug
Project
Indication
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Approval
Country
MT921
Lipolysis Injection
Korea
Synthetic Drugs Graph
Medical Device
Project
Indication
Discovery
Preclinical
Clinical Trial Stage
Approval
Country
Neuramis®
series *
Deep Facial Wrinkle
Korea
Neuramis®
Volume
Lidocaine
Mid Face Volume
Korea
Neuramis®
Volume
Lidocaine
Mid Face Volume
China
Neuramis®
Deep
Lidocaine
Nasolabial Folds
China
Atiere®
Deep Facial Wrinkle
Korea
Potenfill®
Temporary Penile
Enhancement
Korea
MT942
Post Surgical Adhesion
Prevention
Korea
MT941
Osteoarthritis
-
* Neuramis® Light Lidocaine, Neuramis® Lidocaine, Neuramis® Deep, Neuramis® Deep Lidocaine, Neuramis® Volume Lidocaine
Medical Device Graph
Health Supplements
Project
Indication
Discovery
Preclinical
Clinical Trial Stage
Approval
Country
MT961
Lipolysis
Korea
MT963
Hangover Cure
Korea
Health Supplements Graph